T. Rowe Price Associates
OM icon

T. Rowe Price Associates’s Outset Medical OM Stock Holding History

T. Rowe Price Associates’s Portfolio OM Stock Details OM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Sell
35,622
-3,805
-10% -$16.6K ﹤0.01% 3071
2026
Q1 		$152K Buy
39,427
+10,800
+38% +$44.3K ﹤0.01% 2912
2025
Q4 		$107K Buy
28,627
+13,800
+93% +$118K ﹤0.01% 2935
2025
Q3 		$210K Buy
14,827
+3,400
+30% +$53K ﹤0.01% 2775
2025
Q2 		$220K Buy
+11,427
New +$178K ﹤0.01% 2670
2025
Q1 		– Sell
-2,620
Closed -$44K – 3066
2024
Q4 		$44K Sell
2,620
-2,020
-44% -$25.2K ﹤0.01% 2957
2024
Q3 		$48K Hold
4,640
– – ﹤0.01% 2934
2024
Q2 		$268K Sell
4,640
-869
-16% -$42.6K ﹤0.01% 2466
2024
Q1 		$184K Buy
5,509
+2,366
+75% +$120K ﹤0.01% 2646
2023
Q4 		$256K Buy
3,143
+1,154
+58% +$93.9K ﹤0.01% 2443
2023
Q3 		$325K Buy
1,989
+65
+3% +$15.3K ﹤0.01% 2300
2023
Q2 		$632K Buy
1,924
+574
+43% +$175K ﹤0.01% 2026
2023
Q1 		$373K Sell
1,350
-1,072
-44% -$394K ﹤0.01% 2237
2022
Q4 		$938K Sell
2,422
-66
-3% -$18.6K ﹤0.01% 1805
2022
Q3 		$595K Sell
2,488
-187,449
-99% -$50.2M ﹤0.01% 2039
2022
Q2 		$42.3M Buy
189,937
+28,909
+18% +$12.4M 0.01% 935
2022
Q1 		$110M Buy
161,028
+55,517
+53% +$33.4M 0.01% 700
2021
Q4 		$72.9M Buy
105,511
+2,116
+2% +$1.56M 0.01% 866
2021
Q3 		$76.7M Sell
103,395
-147,281
-59% -$100M 0.01% 860
2021
Q2 		$188M Sell
250,676
-62,614
-20% -$47.9M 0.02% 582
2021
Q1 		$256M Buy
313,290
+2,737
+0.9% +$2.11M 0.03% 484
2020
Q4 		$254M Buy
310,553
+5,261
+2% +$4.05M 0.03% 465
2020
Q3 		$220M Buy
+305,292
New +$251M 0.03% 463

Other funds holding OM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

T. Rowe Price Associates's OM Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Outset Medical (OM) stake by 9.7% in Q2 2026, selling an estimated $16.6K and leaving 35,622 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

T. Rowe Price Associates first reported a position in OM in Q3 2020 and has held it in 23 quarters since. The position peaked at $256M in Q1 2021. 93 funds tracked by Wall St. Rank hold OM as of Q2 2026.

  • T. Rowe Price Associates held 35,622 shares of Outset Medical worth $154K as of Q2 2026.
  • T. Rowe Price Associates sold 3,805 Outset Medical shares in Q2 2026, an estimated $16.6K.
  • Outset Medical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3071 holding.
  • T. Rowe Price Associates first reported a position in Outset Medical in Q3 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Outset Medical position peaked at $256M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Outset Medical as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.